Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALM-IT
NCT06014424Phase 2Recruiting
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cannabidiol in Alzheimer's disease (AD), sponsored by Sunnybrook Health Sciences Centre. Started Sep 2023; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06014424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06014424.